Coherus Stock Price, News & Analysis

Coherus BioSciences (NASDAQ: CHRS) announced final Phase 2 clinical trial data for casdozokitug (casdozo) in combination with atezolizumab and bevacizumab for treating hepatocellular carcinoma (HCC). The trial showed improved results with an overall response rate of 38% (up from 27%) and complete response rate of 17.2% (up from 10.3%).

The study involved 30 treatment-naïve patients with unresectable locally advanced or metastatic HCC. Key findings include median progression-free survival of 8.1 months and disease control rate of 58.6% under RECIST v1.1 criteria. The treatment demonstrated efficacy across both viral and non-viral disease types with no new safety concerns.

Based on these promising results, Coherus has initiated a new randomized Phase 2 study combining casdozo with bevacizumab and toripalimab, expected to enroll up to 72 patients.

Coherus BioSciences (NASDAQ: CHRS) has announced that its senior management will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 5:15 p.m. Pacific Time.

The presentation, which will include a Q&A session, will be accessible via Webcast through a link on the Investor Events Calendar section of the Coherus website. The webcast will be available for replay until February 10, 2025.

For further information, investors can contact Jodi Sievers, VP of Investor Relations & Corporate Communications, at IR@coherus.com.

Coherus BioSciences (NASDAQ: CHRS) will present final Phase 2 clinical trial data for casdozokitug (casdozo) at ASCO-GI 2025. The study evaluated casdozo, an IL-27-antagonistic antibody, in combination with atezolizumab and bevacizumab for treating metastatic hepatocellular carcinoma (HCC).

The company has initiated a new randomized Phase 2 study (NCT06679985) testing casdozo with bevacizumab and toripalimab in first-line HCC patients. This study will enroll up to 72 patients to evaluate safety, efficacy, and Project Optimus dosing of the triplet combination.

Previous Phase 3 HEPATORCH study results showed toripalimab with bevacizumab achieved 25.3% objective response rate versus 6.1% for sorafenib, with median overall survival of 20 months versus 14.5 months.

Coherus BioSciences (NASDAQ: CHRS) has agreed to sell its UDENYCA franchise to Intas Pharmaceuticals for up to $558.4 million, including $483.4 million upfront and $75 million in potential sales milestones. The company will use the proceeds to repay $230 million in convertible notes and $49.1 million in royalty obligations. Post-divestiture, Coherus will focus exclusively on its immuno-oncology portfolio, particularly LOQTORZI, an FDA-approved PD-1 inhibitor, and development of combination therapies. The transaction is expected to close by Q1 2025, subject to shareholder approval and regulatory clearances. The company projects post-close cash runway exceeding two years.

Coherus BioSciences (NASDAQ: CHRS) announced its participation in the 2024 Citi Global Healthcare Conference. Dr. Theresa LaVallee, Chief Development Officer, will be a panelist on the Novel Mechanisms in Oncology Panel scheduled for December 3, 2024, at 3:15 p.m. ET. The panel discussion will be available via webcast through the Investor Events and Presentations section of the Coherus website.

Coherus BioSciences (CHRS) reported Q3 2024 net revenue of $70.8 million, driven by strong growth in UDENYCA® and LOQTORZI® sales. UDENYCA net product sales reached $66.1 million, up 30% quarter-over-quarter and 100% year-over-year, maintaining 28% market share. LOQTORZI sales grew 54% to $5.8 million. The company reported a Q3 net loss of $10.8 million, or $(0.09) per share. Cash position stood at $97.7 million as of September 30, 2024. The company projects combined R&D and SG&A expenses for 2024 to be between $250-260 million.

Coherus BioSciences (NASDAQ: CHRS) has announced it will release its third quarter 2024 financial results after market close on Wednesday, November 6, 2024. The company's management will host a conference call and webcast at 5:00 p.m. ET on the same day to discuss the results and provide a business update. Investors can access the conference call through pre-registration and join the webcast through the company's investor relations website. The financial results press release and related materials will be available before the call on the Coherus investor website.

Coherus BioSciences (NASDAQ: CHRS) reported Q2 2024 financial results and business updates. Key highlights:

• Net revenue of $65.0 million in Q2 2024
• UDENYCA net sales increased 60% year-over-year to $50.9 million
• LOQTORZI net sales of $3.8 million since January 2024 launch
• Phase 1 study of CHS-114 showed promising results in solid tumors
• Appointed Bryan McMichael as new CFO
• Divested YUSIMRY franchise for $40 million
• Net loss of $12.9 million or $(0.11) per diluted share in Q2 2024
• Cash and investments of $159.2 million as of June 30, 2024
• Projected 2024 R&D and SG&A expenses of $250-$265 million

Coherus BioSciences, Inc. (NASDAQ: CHRS) has announced that it will release its second quarter 2024 financial results after market close on Thursday, August 8, 2024. The company's management team will host a conference call and webcast at 5:00 p.m. EDT on the same day to discuss the results and provide a general business update.

Investors and interested parties can pre-register for the conference call to receive dial-in information and a personal PIN. A live webcast will be available, and a replay will be accessible on the company's investor relations website. The press release containing the financial results and related materials will be available on the Coherus website before the start of the conference call.